Niacin
Niacin, Niacor (niacin) is a small molecule pharmaceutical. Niacin was first approved as Wampocap on 1982-01-01. It is used to treat hypercholesterolemia, hypertriglyceridemia, pellagra, and peripheral vascular diseases in the USA. It is known to target hydroxycarboxylic acid receptor 1, hydroxycarboxylic acid receptor 2, and hydroxycarboxylic acid receptor 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Niacin, Niacor (discontinued: Niacin, Niaspan titration starter pack, Nicolar, Wampocap)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 011010 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 011013 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 011020 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
| 011021 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
| 011054 niacinamide 4% / spironolactone 5% | unapproved drug other | 2020-07-02 |
| 011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
| 011312 niacinamide 4% / tazarotene 0.05% | unapproved drug other | 2020-07-02 |
| 011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
| 011504 dapsone 8.5% / niacinamide 4% | unapproved drug other | 2020-07-02 |
Show 762 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercholesterolemia | HP_0003124 | D006937 | — |
| hypertriglyceridemia | EFO_0004211 | D015228 | — |
| peripheral vascular diseases | EFO_0003875 | D016491 | I73.9 |
| pellagra | — | D010383 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C04: Peripheral vasodilators
— C04A: Peripheral vasodilators
— C04AC: Nicotinic acid and derivatives, peripheral vasodilators
— C04AC01: Nicotinic acid
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AD: Nicotinic acid and derivatives, lipid modifying, plain
— C10AD02: Nicotinic acid
— C10AD52: Nicotinic acid, combinations
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Clinical Trials
691 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyslipidemias | D050171 | HP_0003119 | — | 6 | 4 | 14 | 15 | 7 | 46 |
| Healthy volunteers/patients | — | — | — | 23 | 3 | — | 1 | 13 | 40 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | 4 | 2 | 17 | 3 | 6 | 32 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 5 | 1 | 10 | 6 | 4 | 26 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 7 | 6 | 4 | 3 | 5 | 24 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 3 | 10 | 1 | 8 | 22 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 5 | 4 | 7 | 2 | 5 | 22 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 2 | 5 | 6 | 9 | 22 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 5 | 2 | 3 | 5 | 3 | 18 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | 10 | 5 | 1 | 16 |
Show 70 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | 8 | 1 | — | 1 | 20 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 3 | 3 | 1 | — | 7 | 13 |
| Leukemia | D007938 | — | C95 | 3 | 8 | 1 | — | — | 10 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 4 | — | 3 | 9 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | 3 | 2 | — | 3 | 9 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | 1 | 2 | — | 7 | 9 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 6 | 1 | — | — | 8 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 2 | — | 4 | 7 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 1 | — | 4 | 7 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 2 | — | 3 | 6 |
Show 96 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 3 | 3 | — | — | 9 | 14 |
| Heart failure | D006333 | HP_0001635 | I50 | 3 | 5 | — | — | 3 | 10 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 4 | 2 | — | — | 4 | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 5 | — | — | 1 | 8 |
| Glucose metabolism disorders | D044882 | — | — | 3 | 2 | — | — | 2 | 7 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 5 | — | — | 1 | 7 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 4 | — | — | 2 | 6 |
| Ataxia | D001259 | — | R27.0 | — | 3 | — | — | 2 | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 4 | — | — | 1 | 5 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 2 | — | — | 3 | 5 |
Show 93 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 3 | — | — | — | 1 | 4 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | 1 | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | — | — | — | — | 3 |
| Abdominal obesity | D056128 | HP_0001956 | — | 1 | — | — | — | 2 | 3 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | — | — | — | 2 | 3 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | 2 | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | — | 2 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | — | — | — | 1 | 2 |
| Pregnancy-induced hypertension | D046110 | — | O13 | 1 | — | — | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | 1 | 2 |
Show 40 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | — | 4 | 4 |
| Diet therapy | D004035 | — | — | — | — | — | — | 3 | 3 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 3 | 3 |
| Dietary supplements | D019587 | — | — | — | — | — | — | 3 | 3 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 3 | 3 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | — | — | 3 | 3 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 3 | 3 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 3 | 3 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 3 | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 3 | 3 |
Show 176 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Niacin |
| INN | nicotinic acid |
| Description | Nicotinic acid is a pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. It has a role as an antidote, an antilipemic drug, a vasodilator agent, a metabolite, an EC 3.5.1.19 (nicotinamidase) inhibitor, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a plant metabolite. It is a vitamin B3, a pyridinemonocarboxylic acid and a pyridine alkaloid. It is a conjugate acid of a nicotinate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cccnc1 |
Identifiers
| PDB | — |
| CAS-ID | 59-67-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL573 |
| ChEBI ID | 15940 |
| PubChem CID | 938 |
| DrugBank | DB00627 |
| UNII ID | 2679MF687A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA2
CA2
Organism
Homo sapiens
Gene name
CA2
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 2
Protein synonyms
CA-II, CAC, Carbonate dehydratase II, carbonic anhydrase B, Carbonic anhydrase C, Carbonic anhydrase II, carbonic dehydratase, Cyanamide hydratase CA2, epididymis luminal protein 76, epididymis secretory protein Li 282
Uniprot ID
Mouse ortholog
Car2 (12349)
carbonic anhydrase 2 (Q9DCY9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Niaspan – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Niacin
+
Lovastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Niacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Niacin
+
Simvastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,038 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal 90 dha, Citranatal assure, Citranatal dha, Citranatal essence, Citranatal rx, Healthy mamabe well rounded, Marnatal f, Moms choice rx, Natafort, Nestabs, Nestabs dha, O-cal prenatal vitamin, Pnv prenatal plus multivitamin, Pnv prenatal vitamin, Pnv-select, Pr natal 400, Pr natal 400 ec, Pr natal 430, Pr natal 430 ec, Pre-tabs dha, Prenata, Prenatal plus multivitamin plus dha minicaps, Prenate elite, Primacare, Select ob, Select-ob plus dha, Tricare prenatal, Tristart dha, Vitafol, Vitafol fe plus, Vitafol ob, Vitafol-ob plus dha
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47,559 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use